Table 3.
MR estimates from different methods of assessing the causal effect of CD on BMDs
| BMDs | Step# | No. of SNP | IVW | MBE | WMM | MR-Egger | MR.RAPS | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| β (95%CI) | P value | Cochran Q statistics (df) | P value | β (95%CI) | P value | β (95%CI) | P value | Slope (95%CI) | P value | Intercept (Se) | P value | Cochran Q statistics (df) | P value | β (95%CI) | P value | |||
| CD and TB-BMD | 3 | 103 | − 0.0061 (− 0.016, 0.0040) | 0.24 | 107.79 (102) | 0.33 | 0.0071 (− 0.016, 0.031) | 0.55 | − 0.0018 (− 0.017, 0.013) | 0.81 | 0.0047 (− 0.024, 0.033) | 0.75 | − 0.0015 (0.0019) | 0.43 | 107.12 (101) | 0.32 | − 0.0049 (− 0.015, 0.0056) | 0.36 |
| CD and FN-BMD | 3 | 104 | − 0.019 (− 0.034, − 0.0050) | 0.0083 | 127.33 (103) | 0.052 | − 0.0030 (− 0.036, 0.030) | 0.86 | − 0.019 (− 0.039, 0.0024) | 0.082 | 0.0066 (− 0.033, 0.046) | 0.74 | − 0.0036 (0.0026) | 0.17 | 125.00 (102) | 0.061 | − 0.017 (− 0.032, − 0.0019) | 0.027 |
| CD and LS-BMD | 2 | 107 | − 0.0048 (− 0.021, 0.011) | 0.55 | 125.92 (106) | 0.091 | − 0.025 (− 0.064, 0.014) | 0.21 | − 0.020 (− 0.042, 0.0030) | 0.089 | 0.0084 (− 0.036, 0.053) | 0.71 | − 0.0018 (0.0030) | 0.53 | 125.45 (105) | 0.085 | − 0.0049 (− 0.021, 0.011) | 0.54 |
| CD and FA-BMD | 3 | 108 | 0.010 (− 0.018) | 0.48 | 123.69 (107) | 0.13 | 0.035 (− 0.022, 0.092) | 0.23 | 0.018 (− 0.023, 0.060) | 0.39 | 0.073 (− 0.0039, 0.15) | 0.066 | − 0.0088 (0.0051) | 0.088 | 120.33 (106) | 0.16 | 0.013 (− 0.016, 0.042) | 0.38 |
| CD and TB-BMD(R*) | 3 | 92 | − 0.0072 (− 0.018, 0.0032) | 0.17 | 103.94 (91) | 0.17 | − 0.0082 (− 0.028, 0.012) | 0.43 | − 0.0096 (− 0.027, 0.0082) | 0.29 | − 0.012 (− 0.037, 0.012) | 0.32 | 0.00080 (0.0017) | 0.64 | 103.69 (90) | 0.15 | − 0.0070 (− 0.018, 0.0037) | 0.20 |
| CD and FN-BMD(R*) | 3 | 90 | − 0.022 (− 0.036, − 0.0072) | 0.0034 | 111.59 (89) | 0.053 | − 0.033 (− 0.061, − 0.0062) | 0.018 | − 0.028 (− 0.051, − 0.0049) | 0.018 | − 0.015 (− 0.047, 0.018) | 0.39 | − 0.0011 (0.0023) | 0.63 | 111.30 (88) | 0.047 | − 0.023 (− 0.038, − 0.0073) | 0.0039 |
| CD and LS-BMD(R*) | 3 | 84 | − 0.0022 (− 0.018, 0.013) | 0.78 | 78.79 (83) | 0.61 | − 0.018 (− 0.051, 0.015) | 0.28 | − 0.015 (− 0.041, 0.010) | 0.24 | 0.0024 (− 0.032, 0.036) | 0.89 | − 0.00071 (0.0024) | 0.77 | 78.71 (82) | 0.58 | − 0.0017 (− 0.018, 0.014) | 0.84 |
| CD and FA-BMD(R*) | 3 | 95 | − 0.0095 (− 0.036, 0.017) | 0.49 | 98.95 (94) | 0.34 | 0.0012 (− 0.056, 0.058) | 0.97 | 0.00063 (− 0.039, 0.041) | 0.98 | 0.0062 (− 0.056, 0.069) | 0.85 | − 0.0024 (0.0044) | 0.59 | 98.64 (93) | 0.32 | − 0.0066 (− 0.035, 0.021) | 0.64 |
Step#: 2, MR analysis after removing the SNPs (with P value less than threshold in MR-PRESSO outlier test); 3, MR analysis after removing all the SNPs (with P value less than 1 in MR-PRESSO outlier test); R*, in replication practice
TB-BMD total body bone mineral density, FN-BMD femoral neck bone mineral density, LS-BMD lumbar spine bone mineral density, FA-BMD forearm bone mineral density, β beta coefficient, Se standard error, SNP single nucleotide polymorphism, MR Mendelian randomization, IVW inverse variance weighting, MR-PRESSO MR-Pleiotropy RESidual Sum and Outlier method, MBE mode-based estimate method, WMM weighted median method, MR.RAPS robust adjusted profile score